Treatment with SKY-0515 results in dose-dependent reductions of mHTT protein in blood of 62% at the 9mg dose, and ...
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 ...
Treatment with SKY-0515 results in dose-dependent reductions of mHTT protein in blood of 62% at the 9mg dose, and dose-dependent PMS1 mRNA reduction of 26%. PMS1 is a key driver of somatic CAG repeat ...
The Daily Galaxy on MSN
Human bodies begin to break down at two surprisingly precise ages, and it’s not gradual
Aging has traditionally been viewed as a gradual and continuous process shaped by time, genetics, and environment. However, ...
Explore how modifying the microbiota may help rebalance the microbiome and improve menopause-related outcomes.
Petal size is a defining trait of ornamental flowers, directly shaping visual appeal and commercial value. A new study ...
IMMUNOLIFE, a Phase 2 randomized exploratory study, will evaluate the potential of MaaT033 in combination with Cemiplimab versus Best Investigator Choice (i.e.: second line) in enhancing disease ...
MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...
Morning Overview on MSN
Scientists find shocking new allies against a major human health threat
Antibiotic resistance and metabolic disease are usually framed as enemies that outsmart medicine at every turn. Yet in ...
London-based Hypercritical has raised £2 million in pre-seed funding to accelerate development of its foundation model and expand its engineering team. The round was led by Join Capital, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results